Rosiglitazone Induction of Insig-1 in White Adipose Tissue Reveals a Novel Interplay of Peroxisome Proliferator-activated Receptor γ and Sterol Regulatory Element-binding Protein in the Regulation of Adipogenesis*

Insulin-induced gene 1 (INSIG-1) is a key regulator in the processing of the sterol regulatory element-binding proteins (SREBPs). We demonstrated that Insig-1 is regulated by peroxisome proliferator-activated receptor γ (PPARγ) providing a link between insulin sensitization/glucose homeostasis and lipid homeostasis. Insig-1 was identified as a PPARγ target gene using microarray analysis of mRNA from the white adipose tissue of diabetic (db/db) animals treated with PPARγ agonists. Insig-1 was induced in subcutaneous (9-fold) and epididymal (4-fold) fat pads from db/db mice treated for 8 days with the PPARγ agonist rosiglitazone (30 mg/kg/day). This in vivo response was confirmed in differentiated C3H10T1/2 adipocytes treated with rosiglitazone. To elucidate the molecular mechanisms regulating INSIG-1 expression, we cloned and characterized the human INSIG-1 promoter. Co-expression of PPARγ and RXRα transactivated the INSIG-1 promoter in the presence of PPARγ agonists. This induction was attenuated when a dominant negative PPARγ construct was transfected into cells. Furthermore, a PPARγ antagonist repressed the transactivation of the INSIG-1 promoter-reporter construct. Truncations of the promoter resulted in the identification of a PPAR response element that mediated the regulation of the promoter. We demonstrated with recombinant proteins that the PPARγ/RXRα heterodimer binds directly to this PPAR response element. In addition to regulation by PPARγ/RXRα, we demonstrated that the INSIG-1 promoter is regulated by transcriptionally active SREBP. The sterol response element was identified 380 base pairs upstream of the transcriptional start site. These findings suggest that the regulation of Insig-1 by PPARγ agonists could in turn regulate SREBP processing and thus couple insulin sensitizers with the regulation of lipid homeostasis.

[1]  Jinping Li,et al.  Insig-1 “brakes” lipogenesis in adipocytes and inhibits differentiation of preadipocytes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Auwerx.  PPARγ, the ultimate thrifty gene , 1999, Diabetologia.

[3]  T. Osborne,et al.  Sterol Regulatory Element-binding Proteins (SREBPs): Key Regulators of Nutritional Homeostasis and Insulin Action* , 2000, The Journal of Biological Chemistry.

[4]  R. Taub,et al.  Novel delayed-early and highly insulin-induced growth response genes. Identification of HRS, a potential regulator of alternative pre-mRNA splicing. , 1993, The Journal of biological chemistry.

[5]  S. Grundy,et al.  Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. , 2003, Circulation.

[6]  S. O’Rahilly,et al.  The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor γ and Its Therapeutic Modulation , 2003 .

[7]  T. Willson,et al.  Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase , 1999, Nature.

[8]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[9]  J. Fleckner,et al.  Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation. , 2002, Diabetes.

[10]  Jay D. Horton,et al.  Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Trautwein,et al.  Insulin and Sterol-regulatory Element-binding Protein-1c (SREBP-1C) Regulation of Gene Expression in 3T3-L1 Adipocytes , 2002, The Journal of Biological Chemistry.

[12]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.

[13]  R. Aebersold,et al.  Crucial Step in Cholesterol Homeostasis Sterols Promote Binding of SCAP to INSIG-1, a Membrane Protein that Facilitates Retention of SREBPs in ER , 2002, Cell.

[14]  J. Goldstein,et al.  Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Goldstein,et al.  Liver-specific mRNA for Insig-2 down-regulated by insulin: Implications for fatty acid synthesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  N. Spinner,et al.  Cloning, human chromosomal assignment, and adipose and hepatic expression of the CL-6/INSIG1 gene. , 1997, Genomics.

[17]  B. Spiegelman,et al.  ADD1/SREBP1 activates PPARγ through the production of endogenous ligand , 1998 .

[18]  B. A. Janowski.  The hypocholesterolemic agent LY295427 up-regulates INSIG-1, identifying the INSIG-1 protein as a mediator of cholesterol homeostasis through SREBP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  B. Spiegelman,et al.  Identification of Conserved cis-Elements and Transcription Factors Required for Sterol-regulated Transcription of Stearoyl-CoA Desaturase 1 and 2* , 1999, The Journal of Biological Chemistry.

[20]  J. Olefsky,et al.  Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes , 1996, Diabetes.

[21]  B. Spiegelman,et al.  Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. , 1998, The Journal of clinical investigation.

[22]  R. Hammer,et al.  Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Flier,et al.  ADD-1 provides major new insight into the mechanism of insulin action. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Larsen,et al.  PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? , 2003, International Journal of Obesity.